免疫检查点分子在肝细胞癌的发展中信号调节蛋白α
Xue Zhang1, Dong-Bo Chen1, Rui Zhang2
1Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Peking University People's Hospital, Beijing 100044, China.
肝细胞癌 (HCC) 免疫疗法在目前的方法中表现出有限的成功. 信号调节蛋白α (SIRPα) 通过调节肝癌中的免疫反应,为增强癌症治疗提供了一个有希望的新目标.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝细胞癌 (HCC) 是全球癌症死亡的主要原因.
- 目前的免疫检查点抑制剂疗法 (例如,抗PD-1/PD-L1) 仅在~20%的晚期HCC病例中有效.
- 这凸显了对HCC新型免疫治疗点的需求.
研究的目的:
- 审查目前对肝细胞癌 (HCC) 中信号调节蛋白α (SIRPα) 的理解.
- 探索SIRPα作为改善HCC免疫疗法的潜在治疗点.
- 确定在HCC中基于SIRPα的疗法所面临的挑战和未来研究方向.
主要方法:
- 关于SIRPα和HCC的最近研究的文献综述.
- 分析SIRPα作为细胞检查点在瘤微环境中的免疫细胞中的作用.
- 综合当前的研究进展和治疗策略.
主要成果:
- 鉴定出SIRPα是巨细胞和其他免疫细胞中显著的细胞检查点.
- SIRPα调节显示了在各种癌症中增强抗瘤免疫力的潜力.
- 新出现的证据表明SIRPα在HCC免疫格局中的关键作用.
结论:
- 在肝细胞癌免疫治疗中,SIRPα 是一个有前途的新型治疗点.
- 向SIRPα可以克服对现有免疫疗法的耐药性.
- 进一步的研究至关重要,以充分阐明SIRPα的作用,并为HCC开发有效的治疗策略.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
相关概念视频
Regulation of Angiogenesis and Blood Supply
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Positive Regulator Molecules
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
